New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
11:00 EDTAZNAstraZeneca unit says MEDI4736 studies showed clinical activity
MedImmune, the biologics research and development arm of AstraZeneca, presented results from its novel investigational immunotherapy portfolio, focusing on MEDI4736, at the American Society of Clinical Oncology meeting. "Overall, studies demonstrated durable and tolerability for MEDI4736 across a range of tumor types," the company said. In a Phase I dose-escalation study of MEDI4736 in 27 patients with advanced solid tumors, reduction of tumor burden was seen at multiple dose levels in as early as six weeks. Clinical activity was maintained for at least one year, with 19% of patients achieving a partial response and 39% of patients achieving disease control. "There was a very low frequency of drug-related serious adverse events, and no dose-limiting toxicities were observed," Medimmune added.
News For AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
11:13 EDTAZNBofA/Merrill European pharma analyst holds an analyst/industry conference call
Subscribe for More Information
March 23, 2015
09:45 EDTAZNUBS to hold a field trip
Subscribe for More Information
09:06 EDTAZNInsmed appoints Eugene Sullivan as Chief Medical and Scientific Officer
Subscribe for More Information
09:03 EDTAZNLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
07:36 EDTAZNPfizer should rise 'significantly' over next two years, says Jefferies
Jefferies analyst Jeffrey Holford told investors this morning that he expects shares of Pfizer (PFE) to appreciate "significantly" over the next two years. A survey of U.S. oncologists indicated the company's Ibrance drug will be used in 50% of first line hormonal therapy within one year, with off-label use in all lines of therapy including adjuvant, Holford noted. He thinks peak sales of the drug could top $13B, which is well above consensus. In addition, the analyst views Pfizer's Global Established Pharmaceutical business as being underappreciated by the market. Potential value creating options for the pharmaceutical giant include spinning off its GEP unit by 2017 and accretive acquisitions, with possible takeover targets being Shire (SHPG), Actavis (ACT), AstraZeneca (AZN) and GlaxoSmithKline (GSK), in the eyes of Holford. He added the stock to the firm's Franchise Picks list, which encompasses its best ideas. He also raised his price target for Pfizer to $45 from $42. The stock closed Friday up 10c to $34.25.
March 20, 2015
07:55 EDTAZNAstraZeneca seen as potential target again if oncology drugs lag, Bloomberg says
Subscribe for More Information
March 19, 2015
08:37 EDTAZNNektar and Daiichi Sankyo to commercialize Movantik in the U.S.
Subscribe for More Information
March 17, 2015
14:10 EDTAZNIGI Laboratories recent sell-off a buying opportunity, says Craig-Hallum
Subscribe for More Information
March 16, 2015
07:30 EDTAZNAmerican College of Cardiology to hold an expo
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use